Ark Genomic Revolution ETF

Guardant Health Inc. collaborates with Trial Library to enhance cancer clinical trial accessibility

Guardant Health's CTO Darya Chudova Sells 22,935 Shares

Guardant Health Inc executive Kalia Kumud sold 2,000 shares

Guardant Health Director Disposes of Company Common Stock

Natera Announces Signatera MRD Test as Prognostic Biomarker for Breast Cancer Recurrence Risk

Tempus AI Presents Machine Learning Model for Metastatic Breast Cancer Treatment Response at SABCS 2025

Cerity Partners LLC Increases Stake in Natera, Inc.

Natera Director Chapman Reports Disposition of Common Stock

Tempus AI Director Reports Sale of Class A Common Stock

Cathie Wood Increases Investments in AI and Autonomous Driving Companies

Wedbush Maintains Buy Rating on Beam Therapeutics

Tempus AI to Present Breast Cancer Research Findings at San Antonio Breast Cancer Symposium

Guardant Health Launches Liquid Biopsy Service in Italy Based on Guardant360® CDx

Hood River Capital Management LLC Increases Holdings in Guardant Health

Norwegian Bank Buys CRISPR Therapeutics Shares, CEO Cuts Holdings

Recursion Pharmaceuticals Shares Show Initial Rebound, Undervalued and Advised for Exploration of Investment Opportunities

Cathie Wood's ARK Invest bought shares of Tempus AI (TEM) on December 8th.

Guardant Health Inc CFO sells stocks

Guardant Health Director Clark Ian T Sold 28,611 Shares

Guardant Health Inc.'s CBO Chris Freeman Reports Sale of Company Common Stock

Beasley Broadcast

NXG CUSHING MIDSTREAM ENERGY F COM 0.001(S/R 11/12/2025)

HeartBeam

Enveric Biosciences

Biodexa Pharmaceuticals

A SPAC III Acquisition

Irobot

Creative Global Tech

Mawson Infrastructure

Photronics

Guardant Health Inc. has partnered with Trial Library to enhance access to cancer clinical trials in the U.S. by integrating genomic data with AI-powered patient matching. This collaboration aims to improve enrollment of diverse patient populations in precision oncology trials, offering new treatment opportunities and boosting participation in cancer research.

Reuters

Guardant Health

Guardant Health Partners with Trial Library to Expand Access to Cancer Clinical Trials

10x Genomics received a Hold rating and price target from Citi analyst today.TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off 10x Genomics has an analyst consensus of Moderate Buy, with a price target consensus of $16.75.

Tip Ranks

10X Genomics

Citi downgrades 10x Genomics (TXG) to a Hold

Guardant Health Insider Sold Shares Worth $10,505,474, According to a Recent SEC Filing

marketscreener

Guardant Health Insider Sold Shares Worth $10,505,474, According to a Recent SEC Filing

03:41 AM EST, 12/11/2025 (MT Newswires) -- Darya Chudova, Chief Technology Officer, on December 08, 2025, sold 22,935 shares in Guardant Health ( GH ) for $2,417,980. Following the Form 4 filing with the SEC, Chudova has control over a total of 66,943 common shares of the company, with 12,463 shares held directly and 54,480 controlled indirectly.SEC Filing: MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

fidelity

Guardant Health Insider Sold Shares Worth $2,417,980, According to a Recent SEC Filing

NTRA

Natera, Inc. and Alliance Foundation Trials, LLC announced initial results from the Phase III PALLAS study at SABCS. The study shows that MRD status, measured by Signatera, is a prognostic biomarker for recurrence risk in stage II-III HR+/HER2- breast cancer. Findings support integrating MRD testing into post-surgical risk assessment for personalized management. Key results include high DRFI for MRD-negative patients, indicating low recurrence risk. Palbociclib is not approved in EBC.

Natera

Natera, Inc. and Alliance Foundation Trials, LLC Announces Initial Translational Research Results from the International Randomized Phase III PALLAS Study

Talasaz AmirAli Chief Executive Officer of Guardant Health Inc [GH] filed a Form 4 on December 10, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/8/25TransactionSaleShares100,000Price$105.05Value$10,505,480Ending Holdings: 855,746 - IndirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

CEO Talasaz Sells 100,000 ($10.5M) Of Guardant Health Inc [GH]

Kalia Kumud Officer of Guardant Health Inc [GH] filed a Form 4 on December 10, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/8/25TransactionSaleShares2,000Price$104.60Value$209,204Ending Holdings: 22,365 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Officer Kalia Sells 2,000 ($209.2K) Of Guardant Health Inc [GH]

Chudova Darya Officer of Guardant Health Inc [GH] filed a Form 4 on December 10, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/8/25TransactionSaleShares22,935Price$105.43Value$2,417,980Ending Holdings: 66,943 (12,463 - Direct, 54,480 - Indirect) For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Officer Chudova Sells 22,935 ($2.4M) Of Guardant Health Inc [GH]

Manuel Hidalgo Medina, a director at Guardant Health Inc., has reported the disposal of common shares of the company. This information was published by Guardant Health Inc. via the EDGAR system of the U.S. Securities and Exchange Commission on December 10, 2025. The news is generated by Public Technologies using AI and is for informational purposes only.

Director Manuel Hidalgo Medina Reports Disposal of Guardant Health Inc. Common Shares

Natera Inc. announced initial results from the Phase III PALLAS study, showing that the Signatera MRD test is a highly prognostic biomarker for distant recurrence risk in stage II-III HR+/HER2- breast cancer. The study involved 420 patients and was presented at the San Antonio Breast Cancer Symposium. Further data from an ex-US cohort and treatment subgroup analysis will be shared later.

Natera Reports Signatera MRD Test Predicts Recurrence Risk in Early-Stage HR+/HER2- Breast Cancer

ILMN

Shares of Illumina Inc. (ILMN) rose 2.10% to $134.91 on Wednesday, outperforming competitors in a strong trading session. The S&P 500 Index rose 0.67% and the Dow Jones Industrial Average rose 1.05%. This marked the stock's second consecutive day of gains, closing 11.86% short of its 52-week high. Competitors had mixed performances: Labcorp Holdings Inc. (LH) rose 1.52%, Charles River Laboratories International Inc. (CRL) rose 4.76%, and Quest Diagnostics Inc. (DGX) fell 0.06%. Trading volume matched its 50-day average of 1.8M.

Dow Jones

Illumina

Illumina Inc. Stock Outperforms Competitors On Strong Trading Day

RXRX

Recursion Pharmaceuticals' REC-4881 trial success in reducing polyp burden in familial adenomatous polyposis patients is seen as a validation of its AI-driven drug discovery platform. This could reshape investment perceptions, highlighting potential upside despite ongoing risks like cash burn and funding needs. The company's narrative projects significant revenue and earnings by 2028, with varying fair value estimates. Investors are encouraged to explore different perspectives and consider the company's financial health and risks before making investment decisions.

Simplywall

Recursion Pharmaceuticals

Is Early REC-4881 Trial Success Reframing the AI-Drug Discovery Investment Case For Recursion (RXRX)?

Natera, Inc. announced initial results from the Phase III PALLAS study, showing that Signatera MRD testing provides significant post-surgical prognostic information for patients with stage II-III HR+/HER2- breast cancer. The study found that MRD-negative patients had a low risk of distant recurrence, while MRD-positive patients had a high risk. These findings support integrating MRD testing into routine post-surgical risk assessment for personalized treatment. The results were presented at the San Antonio Breast Cancer Symposium.

StockTitan

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer | NTRA Stock News

CRSP

The global Plant Breeding and CRISPR Plants market is valued at $21.7 billion in 2024 and is expected to reach $50.1 billion by 2030, with a CAGR of 15%. Regulatory support is enhancing adoption. A report from ResearchAndMarkets.com provides insights into market trends and projections to aid business decisions.

Unusual Whales

CRISPR Therap

Global Plant Breeding and CRISPR Plants market valued at $21.7B in 2024, expected to reach $50.1B by 2030 with 15% CAGR. Regulatory support boosts adoption.